A>I(G) RNA Editing in genotoxic drug response in breast cancer

Simple item page
dc.contributor.advisorArmisen Yañez, Ricardo
dc.contributor.authorBernal Gómez, Yanara Alejandra
dc.coverage.spatialSantiago
dc.date.accessioned2025-03-04T20:08:48Z
dc.date.available2025-03-04T20:08:48Z
dc.date.issued2025
dc.descriptionThesis submitted in partial fulfillment of the requirements for the degree of Doctor of Science in Science and Innovation in Medicine from Faculty of Medicine, Clínica Alemana de Santiago, Universidad del Desarrollo.
dc.description.abstractBreast cancer (BC) is the most common malignancy among women and a leading cause of cancer-related mortality. While advancements in genomic technologies have improved the understanding of BC biology, therapeutic resistance remains a significant challenge, particularly to genotoxic drugs. This study explores the association of A>I(G) RNA editing, a post-transcriptional modification mediated by ADAR enzymes, in drug response and resistance in BC. A>I(G) RNA editing modifies adenosine to inosine in double-stranded RNA, potentially altering RNA stability, splicing, and protein function. The results identified ADAR1-mediated A>I(G) RNA editing sites associated with sensitivity or resistance to genotoxic drugs in BC cell lines. These sites, predominantly located in non-coding regions, were functionally linked to genes involved in DNA damage repair, immune response, and cancer progression. Furthermore, RNA editing levels in genes such as LSR, SMPDL3B, HTRA4, and LL22NC03-80A10.6 were significantly associated with progression-free survival in BC patients, highlighting their potential as prognostic biomarkers. In addition, multi-omics data were integrated using machine learning tools to predict the risk of therapy non-response in BC. This approach identified ADAR1 mediated RNA-edited sites, such as those in KDM4B, miRNA200/TTLL10-AS1, and BEST1, as key predictive variables alongside clinically relevant features. These sites, primarily in non-coding regions, were associated with genes involved in histone demethylation, DNA damage repair (DDR), epithelial-mesenchymal transition (EMT), and cell proliferation. The predictive models demonstrated acceptable performance in distinguishing responder and non-responder patients, emphasizing the utility of combining transcriptomic, epitranscriptomic, and clinical data to predict therapy response and their potential as predictive biomarkers. This study advances the understanding of A>I(G) RNA editing as a contributor to drug resistance in BC and underscores its potential as a biomarker and therapeutic target. The findings highlight the importance of post-transcriptional modifications in precision medicine, offering new avenues for the development of personalized treatment strategies.
dc.format.extent171 p., art.
dc.identifier.urihttps://hdl.handle.net/11447/9894
dc.language.isoen
dc.publisherUniversidad del Desarrollo. Facultad de Medicina
dc.subjectBreast cancer
dc.subjectDrug response
dc.subjectRNA editing
dc.subject090036S
dc.titleA>I(G) RNA Editing in genotoxic drug response in breast cancer
dc.typeThesis
dcterms.accessRightsEmbargo

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
Tesis Doctoral - Yanara Bernal DCIM 2025.pdf
Size:
17.49 MB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
347 B
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Tesis Doctorales

Implementado por OpenGeek Services